This post was originally published on this site Advaxis and Bristol-Myers Squibb have entered a clinical collaboration to evaluate the second generation of axalimogene filolisbac, called ADXS-DUAL, in combination with Opdivo (nivolumab) in women with metastatic cervical cancer. In particular, the study will assess the combination in patients with persistent, recurrent or metastatic (squamous or…
This post was originally published on this site Merck’s Keytruda (pembrolizumab) shows promise as a treatment for advanced, previously treated cervical squamous cell cancer, according to a preliminary analysis of a Phase 2 trial. The data, which will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, indicated response…
This post was originally published on this site Locally advanced cervical cancer (LACC) may be treated with a combination of neoadjuvant chemotherapy (administered before surgery) and p53 gene therapy, according to a new clinical trial. The trial results, titled “Efficacy of recombinant human adenovirus-p53 combined with chemotherapy for locally advanced cervical cancer: A clinical trial,”…
This post was originally published on this site A new diagnostic system by Mel-Mont Medical that allows women to collect cervical cell samples at home could help boost cervical cancer screening in areas where women lack access to health services. This could help prevent unnecessary deaths caused by this preventable disease, the company said. The system, called Mía…
This post was originally published on this site One of nine cervical cancer patients treated with AXAL achieved a long-lasting partial response to the therapy, according to a Phase 1 study. The treatment’s maker, Advaxis, presented the results in a poster session at a National Cancer Research Institute conference in Liverpool, England. The trial covered patients with persistent or…
This post was originally published on this site Synthetic Genomics and Advaxis have developed a current good manufacturing practice (cGMP) synthetic biology suite to produce synthetic DNA constructs. The cGMP facility meets U.S. Food and Drug Administration (FDA) requirements to begin a Phase 1 clinical trial testing ADXS-NEO — a potential immunotherapy made by Advaxis to treat a…
This post was originally published on this site Adding S-1 to Platinol (cisplatin) chemotherapy improved cervical cancer patients’ response to treatment and lengthened the time it took for their disease to progress, according to a Phase 3 clinical trial. Taiho Pharmaceutical, which developed S-1, presented the results at the American Society of Clinical Oncology annual meeting in…
This post was originally published on this site Preliminary data from a Phase 1/2 trial, presented at the American Society of Clinical Oncology Annual 2017 Annual Meeting, shows that Opdivo (nivolumab) monotherapy was effective in more than 26 percent of patients with cervical cancer, regardless of their PD-L1 or HPV status, or number of prior…
